Vexabax 600 mg/300 mg FC Tablets
PDF Leaflet Revision Date: 08 April 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of HIV infection in adults and adolescents from 12 years of age, weighing at least 40 kg.
Dosage (summary)
One tablet once daily for adults and adolescents weighing at least 40 kg.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy or lactation due to potential risks.
Key Drug Interactions
- Ethanol increases abacavir AUC by 41%
- Trimethoprim increases lamivudine exposure by 40%
Contraindications
- Hypersensitivity to abacavir or lamivudine
- Moderate and severe hepatic impairment
- Children below 12 years of age weighing less than 40 kg
Common side effects
- Nausea
- Vomiting
- Diarrhoea
- Rash
- Fever
- Fatigue
Counselling Points
- Inform patients about hypersensitivity risks and symptoms.
- Do not restart VEXABAX after hypersensitivity reaction.
- Patients should contact their doctor immediately if symptoms occur.
Serious warnings
- Risk of life-threatening hypersensitivity reactions
- Lactic acidosis
- Severe hepatomegaly with steatosis
Important Disclaimer
The Vexabax 600 mg/300 mg FC Tablets professional information leaflet below is the property of Ranbaxy Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
